Clonidine controlled release

Drug Profile

Clonidine controlled release

Alternative Names: CloniBID; Clonicel; clonidine HCl sustained release; Jenloga XR; Kapvay

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Addrenex Pharmaceuticals
  • Developer Concordia Pharmaceuticals
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Market Withdrawal Hypertension

Most Recent Events

  • 08 Oct 2013 Generic equivalent available in USA for Attention deficit hyperactivity disorder
  • 07 May 2013 Concordia Pharmaceuticals acquires Clonidine controlled release from Shionogi
  • 10 Jan 2011 Launched for Attention-deficit hyperactivity disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top